Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€5.75

€5.75

-0.880%
-0.05
-0.880%
€7.50
 
27.03.24 / Tradegate WKN: A2JNZJ / Name: Autolus Therapeutics Ltd. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Autolus Therapeutics Ltd. Stock

The price for the Autolus Therapeutics Ltd. stock decreased slightly today. Compared to yesterday there is a change of -€0.050 (-0.880%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Autolus Therapeutics Ltd. stock is not clear.
As a result the target price of 7 € shows a positive potential of 21.74% compared to the current price of 5.75 € for Autolus Therapeutics Ltd..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Autolus Therapeutics Ltd. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Autolus Therapeutics Ltd. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-15

The financials of Autolus Therapeutics Ltd., a company operating within the industry, suggest mixed performance results. On the one hand, there are clear signs of growth, increased assets and revenue, and ongoing investment in research and development. On the other hand, the company continues to show net losses, increasing liabilities, and negative free cash flow. The following analysis delves into these various aspects, providing a more comprehensive view of Autolus Therapeutics Ltd.'s financial situation.

Growth in Total Assets: Over the past three years, Autolus Therapeutics has seen a steady increase in total assets from $294 million in 2020 to $490 million in 2022. This growth may suggest that the company is gradually becoming more valuable and capable of generating higher returns in the future.

R&D Investment: Autolus has consistently invested in research and development, with expenses increasing from $134 million in 2020 to $142 million in 2022. This commitment to R&D is a strong signal that the company is dedicated to innovation, developing novel products, or enhancing existing ones, which could ultimately lead to growth and improved profitability.